|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:activeIngredient
|
fentanyl
|
|
gptkbp:antidote
|
gptkb:naloxone
|
|
gptkbp:approvedBy
|
1960
|
|
gptkbp:ATCCode
|
N01AH01
|
|
gptkbp:brand
|
gptkb:Actiq
Duragesic
Sublimaze
|
|
gptkbp:CASNumber
|
990-73-8
|
|
gptkbp:contraindication
|
acute asthma
paralytic ileus
severe respiratory depression
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Janssen
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
musical composition
injection
nasal spray
lozenge
|
|
gptkbp:halfLife
|
3-12 hours
|
|
gptkbp:hasMolecularFormula
|
C22H28N2O·C6H8O7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fentanyl citrate
|
|
gptkbp:isSaltOf
|
fentanyl
|
|
gptkbp:legalStatus
|
controlled substance
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
addiction
overdose
|
|
gptkbp:routeOfAdministration
|
intramuscular
transdermal
intravenous
sublingual
buccal
|
|
gptkbp:sideEffect
|
nausea
constipation
respiratory depression
sedation
|
|
gptkbp:UNII
|
7FLD91C86K
|
|
gptkbp:usedFor
|
pain management
anesthesia
|
|
gptkbp:usedIn
|
chronic pain
breakthrough cancer pain
surgical anesthesia
|
|
gptkbp:bfsParent
|
gptkb:Recuvyra
|
|
gptkbp:bfsLayer
|
7
|